Case number 1:23-cv-00607
AbbVie Inc. v. Prinston Pharmaceutical Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 16, 2023 | 6 | WAIVER OF SERVICE returned executed by AbbVie Inc.: For Prinston Pharmaceutical Inc. waiver sent on 6/16/2023, answer due 8/15/2023. (Tigan, Jeremy) (Entered: 06/16/2023) (1) |
| Jun 16, 2023 | 7 | WAIVER OF SERVICE returned executed by AbbVie Inc.: For Zhejiang Huahai Pharmaceutical Co., Ltd. waiver sent on 6/16/2023, answer due 8/15/2023. (Tigan, Jeremy) (Entered: 06/16/2023) (1) |
| Jun 16, 2023 | 8 | WAIVER OF SERVICE returned executed by AbbVie Inc.: For Solco Healthcare US, LLC waiver sent on 6/16/2023, answer due 8/15/2023. (Tigan, Jeremy) (Entered: 06/16/2023) (1) |
| Jun 16, 2023 | 9 | Amended Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: April 24, 2023. Date of Expiration of Patent: No. 11,542,239 on July 23, 2039. Hatch-Waxman Regulatory Exclusivity Deadline: January 23, 2026. (Tigan, Jeremy) (Entered: 06/16/2023) (3) |
| Jun 2, 2023 | 1 | Complaint* (1) |
| Jun 2, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) (Entered: 06/02/2023) (3) |
| Jun 2, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: April 24, 2023. Date NDA Holder Received Notice: April 24, 2023. Date of Expiration of Patent: July 23, 2039. Hatch-Waxman Regulatory Exclusivity Deadline: January 23, 2026. (twk) (Entered: 06/02/2023) (2) |
| Jun 2, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,542,239 B2. (twk) (Entered: 06/02/2023) (1) |
| Jun 2, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc. (twk) (Entered: 06/02/2023) (2) |
